针对呼吸道疾病中的2型炎症的生物药物的概述
Whitney W Stevens1, Michael E Wechsler2, Tara Carr3
1Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine.
针对2型的生物药物对严重的喘等呼吸道疾病具有显著的益处. 本综述提供了基于证据的建议,根据诊断和患者因素选择最有效的生物治疗方法.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对2型的生物药物彻底改变了呼吸系统疾病的管理,改善了患者的治疗结果,并减少了对全身皮质类固醇的依赖.
- 经批准的生物药物,如本拉利祖马布,杜比卢马布,梅波利祖马布,奥马利祖马布,雷斯利祖马布和特泽佩卢马布,用于严重的喘和其他呼吸道疾病.
研究的目的:
- 为各种呼吸道疾病选择合适的2型生物制剂提供实用,基于证据的建议.
- 引导临床医生选择最有效的生物疗法,当有多种选择可用时.
主要方法:
- 审查当前文献和FDA批准的2型针对呼吸系统疾病的生物药物.
- 分析影响生物选择的临床因素,包括诊断,先前治疗反应和炎症类型.
主要成果:
- 多种生物药物已被批准用于严重的喘,慢性肺炎,带有多炎的eosinophilic granulomatosis以及带有鼻多重症的慢性鼻炎.
- 生物选择需要确认诊断,评估治疗反应,确定2型炎症,并考虑患者特定的因素.
结论:
- 选择最佳的2型生物药物需要全面的方法,平衡临床疗效与实际考虑.
- 个性化医疗策略对于最大限度地发挥呼吸道疾病中生物疗法的益处至关重要.
更多相关视频
10:39Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
08:33A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
Published on: December 15, 2014
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
